• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Associations Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blocker Use, Gastrointestinal Symptoms, and Mortality Among Patients With COVID-19.

作者信息

Tan Nian-Di, Qiu Yun, Xing Xiang-Bin, Ghosh Subrata, Chen Min-Hu, Mao Ren

机构信息

Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; COVID-19 Medical Team, West Campus of Wuhan Union Hospital, Wuhan, China.

Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

出版信息

Gastroenterology. 2020 Sep;159(3):1170-1172.e1. doi: 10.1053/j.gastro.2020.05.034. Epub 2020 May 16.

DOI:10.1053/j.gastro.2020.05.034
PMID:32422208
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7228878/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c444/7228878/e7d9dd524422/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c444/7228878/e7d9dd524422/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c444/7228878/e7d9dd524422/gr1_lrg.jpg

相似文献

1
Associations Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blocker Use, Gastrointestinal Symptoms, and Mortality Among Patients With COVID-19.新型冠状病毒肺炎患者中血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂的使用、胃肠道症状与死亡率之间的关联
Gastroenterology. 2020 Sep;159(3):1170-1172.e1. doi: 10.1053/j.gastro.2020.05.034. Epub 2020 May 16.
2
Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome.高血压合并 COVID-19 患者住院期间持续使用血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂与临床结局改善相关。
J Infect Dis. 2020 Sep 14;222(8):1256-1264. doi: 10.1093/infdis/jiaa447.
3
Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis.在 COVID-19 疫情背景下使用血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂：回顾性分析。
Front Med. 2020 Oct;14(5):601-612. doi: 10.1007/s11684-020-0800-y. Epub 2020 Jul 3.
4
Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.血管紧张素转化酶抑制剂或血管紧张素受体阻滞剂的使用与 COVID-19 诊断和死亡率的关系。
JAMA. 2020 Jul 14;324(2):168-177. doi: 10.1001/jama.2020.11301.
5
The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.肾素血管紧张素系统抑制剂对2019冠状病毒病（COVID-19）患者死亡率的影响：一项系统评价和荟萃分析。
Diabetes Metab Syndr. 2020 Sep-Oct;14(5):983-990. doi: 10.1016/j.dsx.2020.06.047. Epub 2020 Jun 27.
6
Renin-angiotensin system antagonists are associated with lower mortality in hypertensive patients with COVID-19.血管紧张素转化酶抑制剂/血管紧张素Ⅱ受体拮抗剂与 COVID-19 合并高血压患者的死亡率降低相关。
Scott Med J. 2020 Nov;65(4):123-126. doi: 10.1177/0036933020949219. Epub 2020 Aug 17.
7
A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.中国 2 家中心回顾性研究：血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂在高血压合并 COVID-19 患者中的持续使用效果。
Med Sci Monit. 2020 Sep 24;26:e926651. doi: 10.12659/MSM.926651.
8
Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis.肾素-血管紧张素-醛固酮系统抑制剂治疗高血压患者可降低COVID-19死亡率：一项荟萃分析
Hypertension. 2020 Aug;76(2):e13-e14. doi: 10.1161/HYPERTENSIONAHA.120.15572. Epub 2020 May 27.
9
Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China.中国武汉因 2019 年冠状病毒病（COVID-19）感染而住院的高血压患者中，肾素-血管紧张素系统抑制剂与严重程度或死亡风险的关系。
JAMA Cardiol. 2020 Jul 1;5(7):825-830. doi: 10.1001/jamacardio.2020.1624.
10
[Association of hypertension and antihypertensive agents and the severity of COVID-19 pneumonia. A monocentric French prospective study].[高血压及抗高血压药物与新型冠状病毒肺炎严重程度的关联。一项法国单中心前瞻性研究]
Ann Cardiol Angeiol (Paris). 2020 Nov;69(5):247-254. doi: 10.1016/j.ancard.2020.09.030. Epub 2020 Sep 29.

引用本文的文献

1
A Meta-Analysis of the Impact of Using Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin II Receptor Blockers (ARBs) on Mortality, Severity, and Healthcare Resource Utilization in Patients with COVID-19.血管紧张素转换酶抑制剂（ACEIs）或血管紧张素II受体阻滞剂（ARBs）对新型冠状病毒肺炎（COVID-19）患者死亡率、严重程度及医疗资源利用影响的Meta分析
Adv Respir Med. 2025 Feb 18;93(1):4. doi: 10.3390/arm93010004.
2
Intestinal microbiota by angiotensin receptor blocker therapy exerts protective effects against hypertensive damages.血管紧张素受体阻滞剂治疗肠道微生物群对高血压损伤具有保护作用。
Imeta. 2024 Jul 18;3(4):e222. doi: 10.1002/imt2.222. eCollection 2024 Aug.
3

本文引用的文献

1
Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis.新型冠状病毒肺炎患者胃肠道及肝脏受累的表现和预后：系统评价和荟萃分析。
Lancet Gastroenterol Hepatol. 2020 Jul;5(7):667-678. doi: 10.1016/S2468-1253(20)30126-6. Epub 2020 May 12.
2
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.住院 COVID-19 合并高血压患者中血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂的住院使用率与死亡率的关系。
Circ Res. 2020 Jun 5;126(12):1671-1681. doi: 10.1161/CIRCRESAHA.120.317134. Epub 2020 Apr 17.
3
COVID-19-induced gastrointestinal autonomic dysfunction: A systematic review.
新型冠状病毒肺炎所致胃肠自主神经功能障碍：一项系统综述
World J Clin Cases. 2023 Aug 6;11(22):5252-5272. doi: 10.12998/wjcc.v11.i22.5252.
4
Angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers and hemorrhoids: A nationwide, population-based study.血管紧张素转换酶抑制剂/血管紧张素 II 受体阻滞剂与痔疮：一项全国性、基于人群的研究。
Medicine (Baltimore). 2023 Jun 2;102(22):e33875. doi: 10.1097/MD.0000000000033875.
5
Systematic review and meta-analysis of the clinical outcomes of ACEI/ARB in East-Asian patients with COVID-19.系统评价和荟萃分析 ACEI/ARB 在东亚 COVID-19 患者中的临床结局。
PLoS One. 2023 Jan 12;18(1):e0280280. doi: 10.1371/journal.pone.0280280. eCollection 2023.
6
The spike effect of acute respiratory syndrome coronavirus 2 and coronavirus disease 2019 vaccines on blood pressure.急性呼吸综合征冠状病毒 2 型和 2019 年冠状病毒病疫苗对血压的尖峰效应。
Eur J Intern Med. 2023 Mar;109:12-21. doi: 10.1016/j.ejim.2022.12.004. Epub 2022 Dec 13.
7
Small molecule angiotensin converting enzyme inhibitors: A medicinal chemistry perspective.小分子血管紧张素转换酶抑制剂：药物化学视角
Front Pharmacol. 2022 Nov 1;13:968104. doi: 10.3389/fphar.2022.968104. eCollection 2022.
8
Drugs acting on the renin-angiotensin-aldosterone system (RAAS) and deaths of COVID-19 patients: a systematic review and meta-analysis of observational studies.作用于肾素-血管紧张素-醛固酮系统（RAAS）的药物与COVID-19患者死亡：观察性研究的系统评价和荟萃分析
Egypt Heart J. 2022 Sep 6;74(1):64. doi: 10.1186/s43044-022-00303-8.
9
COVID-19, vaccines and deficiency of ACE and other angiotensinases. Closing the loop on the "Spike effect".COVID-19、疫苗和 ACE 及其他血管紧张素转换酶缺乏症。对“刺突效应”闭环。
Eur J Intern Med. 2022 Sep;103:23-28. doi: 10.1016/j.ejim.2022.06.015. Epub 2022 Jun 22.
10
Antihypertensive Therapy by ACEI/ARB Is Associated With Intestinal Flora Alterations and Metabolomic Profiles in Hypertensive Patients.血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体阻滞剂进行的降压治疗与高血压患者肠道菌群改变及代谢组学特征相关。
Front Cell Dev Biol. 2022 Mar 23;10:861829. doi: 10.3389/fcell.2022.861829. eCollection 2022.
Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB.
COVID-19 感染患者服用 ACEI/ARB 的结果。
Curr Cardiol Rep. 2020 Apr 14;22(5):31. doi: 10.1007/s11886-020-01291-4.
4
Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysis.香港队列粪便样本中 SARS-CoV-2 感染的胃肠道表现及病毒载量：系统评价与荟萃分析
Gastroenterology. 2020 Jul;159(1):81-95. doi: 10.1053/j.gastro.2020.03.065. Epub 2020 Apr 3.
5
Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses.单细胞 RNA 测序分析 13 个人体组织样本，鉴定出人类冠状病毒的细胞类型和受体。
Biochem Biophys Res Commun. 2020 May 21;526(1):135-140. doi: 10.1016/j.bbrc.2020.03.044. Epub 2020 Mar 19.
6
Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury.从 2019 年新冠病毒感染患者中提取的临床和生化指标与病毒载量和肺部损伤有关。
Sci China Life Sci. 2020 Mar;63(3):364-374. doi: 10.1007/s11427-020-1643-8. Epub 2020 Feb 9.